FDA Accepts Aquestive’s Anaphylm Resubmission for Review
FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis. The Class 2 review has a target decision date of March 16, 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligen